CENCORA
LIVE

Serial Number

98330220

Owner

Cencora, Inc.

Attorney

Anita B. Polott

Filing Date

Dec 26, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CENCORA Trademark

Serial Number: 98330220

CENCORA is a trademark filed by Cencora, Inc. on December 26, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Cencora, Inc. (74 trademarks)

1 West First Avenue
Conshohocken, PA 19428

Entity Type: 03

Trademark Details

Filing Date

December 26, 2023

Registration Date

Not Registered

Published for Opposition

August 26, 2025

Goods & Services

Scientific and technological services, namely, research and design in the field of new product design and scientific research in the field of pharmacovigilance, clinical data review, chemistry data evaluation; Scientific research and laboratory research, all in the field of pharmaceuticals, medicines and medical products; industrial analysis and research services, namely, laboratory research services relating to pharmaceuticals, pharmaceutical research services, and research and development of new products for others; consulting services for others in the field of design, planning, and implementation project management in the field of pharmaceuticals, medicines and medical products; pharmaceutical product evaluation; consultancy pertaining to pharmacology; consultancy relating to research and development in the field of therapeutics; consultancy relating to laboratory testing of materials; pharmaceutical products development; testing of pharmaceuticals; provision of information and data relating to medical and veterinary research and development; inspection of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries, namely, information technology consulting services relating to computer network design, computer software design, information technology architecture and infrastructure, installation, maintenance and repair of computer software; quality control testing for others; materials testing and evaluation; product safety testing; consulting services for others in the field of design, planning, and implementation project management of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, drug safety, clinical research, clinical testing and clinical trials; Scientific and technological services, namely, research and design in the field of pharmaceutical development, medical devices, and biopharmaceuticals; scientific, technological, medical and pharmaceutical research and development services; industrial analysis and research services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research and development of new products for others; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific, technological, medical research and pharmaceutical research services and analysis services for scientific and technological purposes; biological research; clinical research, namely, scientific research in the nature of conducting clinical trials for others; providing medical research and scientific research information; provision of scientific information in the nature of scientific surveys; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; scientific research in the fields of pharmaceuticals, vaccines, medicine, biologics, biotherapeutics, biosimilars, therapeutics; development of a web application software for entering and evaluating informative texts for pharmaceuticals and medical products, in particular instructions for use, package inserts, specialist information and for the provision of various documents; database services, namely, electronic storage of data in computer databases; conversion of data or documents from physical to electronic media; testing, inspection or research of pharmaceuticals and medicines; design, engineering, research, development and testing services in the field of pharmaceuticals, medical devices, and biopharmaceuticals; research in the field of gene therapy; consultancy relating to quality assurance services, namely, quality assurance, quality control, quality evaluation and analysis in the field of pharmaceuticals, pharmaceutical manufacturing, medical devices, and biopharmaceuticals; research services relating to scientific work; preparation of scientific research analyses and evaluations relating to pharmaceuticals, medical devices, and biopharmaceuticals; development of pharmaceutical preparations and medicines; scientific investigations for medical purposes; conducting early evaluations in the field of new pharmaceuticals; medical research laboratory services; computer services, namely, on-site management of information technology systems for the pharmaceutical and healthcare industries; scientific evaluation of the drugs of others to determine drug efficacy; research and development services for assessing the efficiency of pharmaceuticals; analysis and evaluation of product design for others; analysis and evaluation of product development for others; quality control and evaluation of goods of others to determine conformity with certification standards; quality testing of products for certification purposes; consulting and advice on drug safety and monitoring for product research and development purposes; consultancy services in regard to the development and approval process of therapeutic and diagnostic biological samples and chemical samples​​​​​​​; consultancy services for others in the field of design, planning, implementation and project management of clinical trials, scientific pharmacovigilance research, pharmaceutical and biotechnology product development; consultancy services in the fields of biotechnology, pharmaceutical research and development, laboratory testing of materials and pharmacogenetics; research laboratory analysis services in the fields of pharmaceuticals and development of biotechnology products that are used for medical diagnosis and treatment of persons; Software as a service (SAAS) services featuring software for product development processes and regulatory compliance using artificial intelligence for machine learning in order to supporting decision making processes; Software as a service (SAAS) services featuring software using artificial intelligence for machine learning for supporting decision making processes; Software as a service (SAAS) services featuring software for collecting data related to clinical trials, drug development, and drug safety; Software as a service (SAAS) services, namely, automation software for collecting data related to clinical trials, drug development, and drug safety; providing online non-downloadable computer programs for data processing; providing online non-downloadable unified communications software for integrating software communications systems and software development tools; providing online non-downloadable assistive software for collecting data related to clinical trials, drug development, and drug safety

Filing History

TEAS STATEMENT OF USE RECEIVED
Apr 3, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 21, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 26, 2025 NPUB
PUBLISHED FOR OPPOSITION
Aug 26, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 24, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 24, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 24, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 24, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 24, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 26, 2025 GNFN
FINAL REFUSAL E-MAILED
Apr 26, 2025 GNFR
FINAL REFUSAL WRITTEN
Apr 26, 2025 CNFR
ASSIGNED TO EXAMINER
Feb 18, 2025 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Feb 13, 2025 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Feb 13, 2025 PARI
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 13, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 13, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 13, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Nov 12, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Nov 12, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 13, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 13, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 13, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 8, 2024 NWOS
NEW APPLICATION ENTERED
Dec 26, 2023 NWAP